WNT5A is a putative epi-driver of prostate cancer metastasis to the bone.
Cancer Med
; 13(16): e70122, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-39164966
ABSTRACT
BACKGROUND:
Current diagnostic tools are unable to distinguish low-grade indolent prostate cancer (PrCa) from that with a propensity to become metastatic and/or lethal. Recent evidence suggests that reprogramming of the transcriptome may drive the metastatic phenotype, and that this reprogramming is controlled, at least in part, by epigenetic changes to the DNA of cancer cells, including methylation. These changes, referred to as 'epigenetic drivers,' have previously been associated with cancer cell survival.METHODS:
Here, using Illumina Methylation EPIC array data of paired primary PrCa and metastatic bone samples, we identified WNT5A as a putative epi-driver of PrCa metastasis to the bone, which was further validated in vitro.RESULTS:
Significantly higher WNT5A methylation was observed in primary PrCa samples and 22Rv1 cells compared to metastatic bone samples and PC-3 cells. This higher methylation was associated with significantly lower WNT5A gene expression.CONCLUSION:
Given the limited effective therapies available for metastatic cancer sufferers, particularly those whose disease has metastasised to the bone, WNT5A presents as a potential putative target for therapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Neoplasias Ósseas
/
Regulação Neoplásica da Expressão Gênica
/
Metilação de DNA
/
Epigênese Genética
/
Proteína Wnt-5a
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Cancer Med
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Austrália